HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy
Related Experiment Video
Updated: Mar 8, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Marie Lachâtre1, Armelle Pasquet, Faïza Ajana
1aDepartment of Infectious Diseases, Bichat-Claude-Bernard Hospital, AP-HPbParis Diderot University, Sorbonne Paris Cité, PariscDepartment of Infectious Diseases, Tourcoing Hospital, TourcoingdLaboratory of Biochemistry, Lille Hospital, LilleeDepartment of Nuclear Medicine, Lille Hospital, LillefLaboratory of Virology, Lille Hospital, LillegParis-Saclay University, Paris-Sud University, UVSQ, CESP U1018, INSERMhDepartment of Internal Medicine, Bicêtre Hospital, AP-HPiEA 7327 Paris Descartes University, Paris, France.
Abstract:
Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male hypogonadism among people living with HIV on effective antiretroviral therapy. Male hypogonadism was found in 12.4% of patients, twice the rate reported in the general population of the same age. Two risk thresholds, namely 5 years of antiretroviral therapy and 19% total body fat, may help to identify patients at risk.
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Infertility in Males
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Retroviruses

